中文On May 19, 2025, a 31-member delegation from the Bosnia and Herzegovina Medical Equipment and Technology Training Program, organized by China’s Ministry of Commerce and co-hosted by the International Business Officials Academy and China International Medical Health Co., Ltd., paid a visit to Igenesis (Shanghai) Co., Ltd. The visit aimed to foster pragmatic cooperation in healthcare between China and Bosnia and Herzegovina, while promoting technological exchanges in medical equipment.
“Bosnia and Herzegovina delegation with Igenesis leadership team”
At the company headquarters, Mr. Steve Yu, General Manager, and Mr. Will Li, Overseas Sales Vice President, extended a warm welcome to the delegates. During the symposium, Mr. Li delivered a presentation highlighting Igenesis’ cutting-edge innovations in molecular POCT (Point-of-Care Testing). He elaborated on the company’s growth trajectory, product portfolio, and global expansion strategy, with a focus on the Galaxy Automated Fully Enclosed qPCR Instruments and portable molecular diagnostic solutions. The delegation expressed strong interest in the technology, noting its potential for improving diagnostic efficiency in resource-constrained settings.
“Overseas Sales Vice President briefing delegation on Igenesis’ product solutions”
Following the symposium, the delegation toured Igenesis’ state-of-the-art manufacturing facilities and R&D laboratories, gaining firsthand insights into precision production processes and rigorous quality control systems. Delegates commended the company’s compliance with international certifications (e.g., CE, ISO 13485) and expressed optimism about future collaborations in technology transfer and market access.
“Delegation members inspecting production lines at Igenesis’ facility”
This visit marked a significant step toward establishing long-term partnerships between Igenesis and Bosnian healthcare institutions. Moving forward, Igenesis remains committed to its core values of "Integrity, Excellence, Innovation, and Win-Win," driving global healthcare advancements through continuous R&D and cross-border collaboration. The company looks forward to contributing to Bosnia and Herzegovina’s healthcare modernization through innovative molecular diagnostic solutions.
Post time: May-30-2025